Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Frankly, given how the hRPC trial has developed under his stewardship, I'm not sure how greatly he'll be missed.
As BoH points out, the new direction the company is going in perhaps isn't suited to his skillset in any case.
Think you might be asking the wrong group of people! If any of us were good at predicting where the share price would be in 6 months time, then safe to say we would have sold out a while ago.
But in an attempt to answer your question, the company is currently valued at only around £4 to 5m above its cash reserves, so you would hope/expect that the share price shouldn't drop any more.
The potential for exosomes is huge, but it's difficult to say what will be announced on that front over the next 6 months. Fosun developments could be interesting, but no guarantees.
Investment case surely looks weighted to the upside from these levels. If you're new to the share then a good starting point would be the investor presentation from Friday. Link below...
https://youtu.be/dR_bbiZr_Y4
Looking a bit short of obvious near term catalysts now.
We should expect further collaboration announcements by the sounds of it, which is positive, but obviously the market doesn't value that too highly right now (given we already have 7 ongoing and the share price is on the floor).
Further fosun movement and terms of additional technology transfer are likely to be forthcoming soon. I have no idea how lucrative this would be, but at least it will demonstrate progress and commitment from fosun.
Additional POC exosomes data from one of the global/large pharma collaborations could perhaps be expected in the next 6 months, and this would then presumably lead to licencing negotiations.
Sounds like an equity raise is firmly off the table for now at these levels, but if no licencing deal or fosun milestone payment is secured in the next 12 months then it spells trouble.
All-in-all the investor presentation was interesting to see, and hopefully puts a stop to the share price decline, but doesn't outline an immediate bull case for us to get excited about.
Hopefully something left-field gets announced, but seems like it needs to go in the bottom drawer for the time being. If you're buying at these levels then the upside could be really significant based on any licencing deal terms. Paper losses could well reduce the appetite for further risk here though.
Chester - I think you have summarised the situation very nicely there. Especially the point regarding institutional appetite for pursuing further hprc trials (and associated cost). Now the dust has settled somewhat, it will be interesting to hear them outline their strategy at the investor meeting on the 4th Feb.
Might be difficult to believe based on what's happened recently here, but codiak is actually down more in the last 12 months than Rene (-78% vs -70%).
Not sure if that's a good thing or a bad thing, but it does at least provide some context of how badly small cap biotech has been hammered in the past year, regardless of the individual circumstances.
Sorry, where has this 10 million order been plucked from? I get that stockpiling will occur, but why would they want 10 million doses, and how could SNG realistically produce that amount within a reasonable time frame?
Don't get me wrong, I would be happy to see such an order (and ones from other countries), just not sure how you have arrived at such a figure.
hRPC is being suspended and out licenced specifically to avoid any more capital raise. It's an expensive programme, and the outcome sadly holds less promise than it once did. Ross is a savvy character, and no doubt if he wasn't involved the company would probably have spent another couple of years looking at further phase 2a studies, along with a significant fund raise and a full scale obliteration of shareholder value with no certain outcome.
However, on a brighter note, the chances of them securing an exosomes deal haven't changed since the hRPC RNS of last week. If/when they can secure such an outcome, then the landscape would change fundamentally overnight, and from the current share price level it could bring some very significant upside.
I still haven't been able to bring myself to buy any more since the RNS (thankfully), however it is now so cheap that it's almost being valued on a cash basis. You would presume that it has to bounce at some point, but sentiment is so shattered right now that nobody appears to be willing to catch the knife.
I think it's recognition that it's the exosomes that are responsible for how the treatment actually works. That doesn't mean that injecting the CTX cells isn't a valid way to treat the patients, instead it suggests that if they were starting again now then they would be designing the study in a different way.
CTX is at phase 2b and it has taken over a decade to reach that point. There's no reason why it can't be a commercial product in itself, if the data proves the efficacy of the treatment.
Don't fully know, but I'm presuming the latest RNS relates to how services and expertise are provided by Rene to Fosun, to allow labs and analytics to be set up to the standards required for the cells to be cultured and preserved.
Whereas the April 2019 sets out the terms for how the product will be licenced, milestone payments and royalties. Part of the original deal seems to require Rene to provide all the cells etc, whereas now Fosun seem keen to be able to produce them in house, which Olav implies is good news as it demonstrates a commitment to the programme.
That's my reading anyway. You could email the company and ask for clarification (and post on here if you get a response), as it's not all totally clear to me.
Pretty sure they do want to sign a deal, in fact I would say that is their top priority now.
As a side note, I can't help but think the title of this thread sounds like an episode of Fraiser. Hopefully we're not all in need of a physiatrist for keeping the faith here. . . .
I don't know enough about him to offer any meaningful insight, but the fact that he's involved in a tug of war between two leading exosomes companies suggests that he must certainly be well respected. The fact that he's returning to rene also suggests that he too must be enthused by the POC data they have recently produced. Bodes well.
Hi surprised. They have POC data in hand, which according to the CSO represents the most exciting breakthrough in the 15 years he's been involved in the exosomes field (refer to the preliminary results presentation).
This data is therefore presumably equivalent to, or better than, the kind of pre-clinical POC data that codiak and evox secured their billion dollar collaboration deals on in recent years.
On this basis, assuming the findings can be replicated with one of the ongoing major pharma collaborations, then it seems to me that we could be looking at negotiating a similar kind of deal as and when those data emerge.
Would concur. But now, for me, exosomes deal seems an inevitability. Timescales are uncertain; given that the POC data produced so far is with an academic institution, then we may be reliant on them producing equivalent data with one of their major pharma collaborations, with a deal to then be negotiated off the back of that.
All said, I'm personally very comfortable with where we stand. Picked up two more tranches at 75p and 82p recently, so hopefully some good value moving forwards.
Reneuron consistently stands out amongst its peers as being the one that's worth peanuts.
Its either fundamentally undervalued, or the technology is fundamentally flawed and destined to fail. We'll find out the answer this year without a shadow of doubt (... pretty sure I said that at the start of last year as well, but hey ho).